UBS Group AG Sells 114,454 Shares of Progyny, Inc. $PGNY

UBS Group AG reduced its holdings in shares of Progyny, Inc. (NASDAQ:PGNY) by 47.0% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 129,087 shares of the company’s stock after selling 114,454 shares during the period. UBS Group AG’s holdings in Progyny were worth $3,315,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently modified their holdings of PGNY. Principal Financial Group Inc. raised its position in Progyny by 57.1% during the 3rd quarter. Principal Financial Group Inc. now owns 704,267 shares of the company’s stock valued at $15,156,000 after purchasing an additional 256,078 shares in the last quarter. Vanguard Group Inc. raised its position in Progyny by 2.4% during the 3rd quarter. Vanguard Group Inc. now owns 10,106,147 shares of the company’s stock valued at $217,484,000 after purchasing an additional 235,513 shares in the last quarter. Intech Investment Management LLC raised its position in Progyny by 336.0% during the 3rd quarter. Intech Investment Management LLC now owns 169,834 shares of the company’s stock valued at $3,655,000 after purchasing an additional 130,885 shares in the last quarter. Algert Global LLC raised its position in Progyny by 35.1% during the 3rd quarter. Algert Global LLC now owns 595,805 shares of the company’s stock valued at $12,822,000 after purchasing an additional 154,930 shares in the last quarter. Finally, Barclays PLC raised its position in Progyny by 79.2% during the 3rd quarter. Barclays PLC now owns 1,575,470 shares of the company’s stock valued at $33,904,000 after purchasing an additional 696,447 shares in the last quarter. 94.93% of the stock is owned by institutional investors.

Progyny Stock Performance

Shares of NASDAQ:PGNY opened at $24.88 on Monday. Progyny, Inc. has a 12-month low of $16.10 and a 12-month high of $28.75. The business’s fifty day simple moving average is $19.06 and its 200-day simple moving average is $22.06. The company has a market capitalization of $1.95 billion, a PE ratio of 32.31, a P/E/G ratio of 1.32 and a beta of 0.91.

Progyny (NASDAQ:PGNY) last announced its earnings results on Thursday, May 7th. The company reported $0.29 earnings per share for the quarter, topping the consensus estimate of $0.26 by $0.03. The firm had revenue of $328.50 million for the quarter, compared to the consensus estimate of $326.47 million. Progyny had a return on equity of 13.34% and a net margin of 5.23%.The firm’s revenue for the quarter was down 26.4% on a year-over-year basis. During the same period in the previous year, the business earned $0.17 EPS. Progyny has set its FY 2026 guidance at 1.980-2.09 EPS and its Q2 2026 guidance at 0.500-0.53 EPS. Research analysts predict that Progyny, Inc. will post 1.12 EPS for the current year.

Analyst Upgrades and Downgrades

PGNY has been the subject of a number of research analyst reports. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Progyny in a research report on Friday, March 27th. KeyCorp decreased their target price on Progyny from $32.00 to $28.00 and set an “overweight” rating for the company in a research report on Monday, March 2nd. Canaccord Genuity Group raised Progyny from a “hold” rating to a “buy” rating and lifted their target price for the company from $19.00 to $30.00 in a research report on Tuesday, May 19th. Barclays lifted their target price on Progyny from $23.00 to $27.00 and gave the company an “overweight” rating in a research report on Friday, May 15th. Finally, Citizens Jmp lifted their target price on Progyny from $30.00 to $31.00 and gave the company a “market outperform” rating in a research report on Monday, May 11th. One analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating and two have issued a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $29.55.

Insider Buying and Selling at Progyny

In other Progyny news, COO Melissa B. Cummings sold 9,578 shares of the business’s stock in a transaction dated Tuesday, May 19th. The stock was sold at an average price of $25.00, for a total transaction of $239,450.00. Following the sale, the chief operating officer owned 73,371 shares in the company, valued at approximately $1,834,275. The trade was a 11.55% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Allison Swartz sold 4,657 shares of the business’s stock in a transaction dated Tuesday, March 3rd. The shares were sold at an average price of $17.40, for a total value of $81,031.80. Following the sale, the executive vice president owned 89,879 shares in the company, valued at approximately $1,563,894.60. The trade was a 4.93% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 25,308 shares of company stock worth $579,977. 9.90% of the stock is currently owned by insiders.

Progyny Company Profile

Progyny, Inc is a New York-based fertility benefits management company that partners with employers and health plans to design and administer comprehensive family-building programs. The company’s digital health platform integrates clinical expertise, patient support tools and data analytics to help members navigate fertility treatments, from in vitro fertilization (IVF) and egg freezing to surrogacy and adoption. By focusing on outcomes-based care, Progyny aims to improve success rates while controlling costs for its clients.

The core of Progyny’s offering is its proprietary Smart Cycle® benefit, which bundles clinical, emotional and logistical support into a single package.